The Changes Of Interleukin-13 In CSF And The Clinical Study Of Curative Effect Of Drugs In Multiple Sclerosis

Objectives:In this study we observed the dynamic effect of treating the acute stage of MS with methylprednisolone(MPS) combined with simvastatin. Discuss the immunomodulatory effects and some adjuvant treatments in MS, through doing the variation of EDSS scores in different time points, and detecting the concentration of IL-13 before receiving any treatment and post-treatment.Methods:The study was investigating simvastatin as an add-on treatment to MPS for treatment of relapsing-remitting multiple sclerosis.Between September 2012 and December 2014,we enrolled into thirty-eight RRMS patients with acute phase who were aged 14-62 years with clinically definited relapsing-remitting multiple sclerosis as defined by MacDonald criteria and no previous treatment with interferon, immunomodulator, immunosuppressant. Simvatatin group and control group had both nineteen eligible patients. All patients started treatment with intravenous MPS as routine treatment. Simvastatin group was used by routine treatment and simvastatin 40mg/d.Two examining physicians assessed EDSS scores of every patient before treatment and in the 1,2,3,4,8,12 weeks. The CSF (cerebrospinal fluid) levels of IL-13 were detected by ELISA method. The experimental results were analyzed with statistic soft Package of SPSS19.0. Differences between groups were analysed by independent samples t-tests. The significance level was established at P<0.05.Enumeration datas were analysed by Chi-square test.All values are reported as mean±SD.The EDSS scores and the concentration of IL-13 in 4 week and 12 weeks was used for Spearman’s rank correlation analysis.Results:1.We found.in fact,that EDSS of simvastatin group and control group on the 1,2,3,4,8,12weeks declined compared with the values before the treatment, there were statistically difference(P<0.05);2.There were no statistically difference in EDSS of 1,2,3,4weeks between simvastatin group and control group after treatment(P>0.05).3.There were statistically difference in EDSS of 8,12 weeks between simvatatin group and control group after treatment(P<0.05).4.The CSF level of IL-13 in the simvastatin group and the control group after treatment compared with them before treatment have statistically difference(P<0.05) in 4 weeks and 12 weeks.5.The CSF level of IL-13 after treatment in the simvastatin group are elevated significantly (P<0.05) compared to the control group after treatment in 4 weeks and 12weeks.6. The expression of IL-13 in the treatment group were raised in 4 weeks,but which was not correlated with the EDSS. The expression of IL-13 in the treatment group were raised in 12weeks, which correlated with the EDSS.Conclusions:1.Simvastatin combined with MPS can reduce the EDSS scores of MS patients with acute phase after treatment for over 4 weeks.Simvastatin have adjunt therapy in the treatment of MS.2.Elevating the CSF concentration of IL-13 may be one of the mechanisms in the adjuvant treatment of MS...